on Quantum Biopharma Ltd.
Quantum Biopharma Faces Class Action Lawsuit Over Alleged Stock Manipulation
Quantum BioPharma Ltd., a biopharmaceutical company listed on NASDAQ, is involved in a class action lawsuit initiated by shareholder Paul Durkacz. The legal action accuses the Canadian banks, CIBC and RBC, of illegally manipulating the company's stock between January 2021 and October 2025. This alleged manipulation has reportedly harmed shareholders materially.
Quantum BioPharma is seeking to become a lead plaintiff to protect its investors. The company's core focus includes developing treatments for neurodegenerative and metabolic disorders, particularly through its subsidiary Lucid Psycheceuticals Inc. Despite ongoing litigation, Quantum BioPharma continues its strategic investments and product development initiatives.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Quantum Biopharma Ltd. news